These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

796 related items for PubMed ID: 28292264

  • 1. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H, Lu J, Tang J, Chen S, He K, Jiang X, Jiang W, Teng L.
    BMC Cancer; 2017 Mar 14; 17(1):191. PubMed ID: 28292264
    [Abstract] [Full Text] [Related]

  • 2. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X.
    Br J Cancer; 2014 Mar 04; 110(5):1169-78. PubMed ID: 24518603
    [Abstract] [Full Text] [Related]

  • 3. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.
    Clin Cancer Res; 2013 May 01; 19(9):2572-83. PubMed ID: 23493349
    [Abstract] [Full Text] [Related]

  • 4. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, Li W, Li J.
    Oncotarget; 2015 Feb 10; 6(4):2009-22. PubMed ID: 25576915
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY, Jung K, Song JY, Kim S, Shin S, Kwon YJ, Oh E, Park WY, Song SY, Choi YL.
    BMC Cancer; 2017 Aug 10; 17(1):535. PubMed ID: 28806950
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
    Lu J, Li G, He K, Jiang W, Xu C, Li Z, Wang H, Wang W, Wang H, Teng X, Teng L.
    J Transl Med; 2015 Feb 01; 13():42. PubMed ID: 25638174
    [Abstract] [Full Text] [Related]

  • 10. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
    Shin SH, Park SS, Ju EJ, Park J, Ko EJ, Hwang JJ, Suh YA, Jang SJ, Lee JS, Ko BK, Kim KT, Lee JS, Song SY, Jeong SY, Choi EK.
    Anticancer Res; 2018 Jan 01; 38(1):287-293. PubMed ID: 29277785
    [Abstract] [Full Text] [Related]

  • 11. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy.
    Kim JS, Kim MY, Hong S.
    Int J Mol Sci; 2024 May 29; 25(11):. PubMed ID: 38892160
    [Abstract] [Full Text] [Related]

  • 12. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.
    Chen Z, Huang W, Tian T, Zang W, Wang J, Liu Z, Li Z, Lai Y, Jiang Z, Gao J, Shen L.
    J Hematol Oncol; 2018 Feb 13; 11(1):20. PubMed ID: 29433585
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
    Das K, Gunasegaran B, Tan IB, Deng N, Lim KH, Tan P.
    Cancer Lett; 2014 Oct 28; 353(2):167-75. PubMed ID: 25086186
    [Abstract] [Full Text] [Related]

  • 16. M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.
    Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, Choi HW, Yoshimatsu K, Shiina I, Yamori T, Dan S.
    Cancer Res; 2016 Jul 01; 76(13):3895-903. PubMed ID: 27197184
    [Abstract] [Full Text] [Related]

  • 17. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
    Chen Z, Liu Z, Zhang M, Huang W, Li Z, Wang S, Zhang C, Dong B, Gao J, Shen L.
    Int J Cancer; 2019 Nov 01; 145(9):2440-2449. PubMed ID: 30957241
    [Abstract] [Full Text] [Related]

  • 18. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, Ochiai A.
    Gastric Cancer; 2015 Apr 01; 18(2):227-38. PubMed ID: 24626858
    [Abstract] [Full Text] [Related]

  • 19. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
    Jo JC, Choi EK, Shin JS, Moon JH, Hong SW, Lee HR, Kim SM, Jung SA, Lee DH, Jung SH, Lee SH, Kim JE, Kim KP, Hong YS, Suh YA, Jang SJ, Choi EK, Lee JS, Jin DH, Kim TW.
    Mol Cancer Ther; 2015 Nov 01; 14(11):2613-22. PubMed ID: 26351320
    [Abstract] [Full Text] [Related]

  • 20. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
    Huang T, Liu D, Wang Y, Li P, Sun L, Xiong H, Dai Y, Zou M, Yuan X, Qiu H.
    Cell Physiol Biochem; 2018 Nov 01; 50(4):1332-1345. PubMed ID: 30355943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.